Oct. 19 at 11:44 AM
Let's look at the biotech landscape:
$RANI Licensing deal Fri w/Chugai (
$CHGCY).
$60 mil PIPE w/pre-funded warrants. Up 250%. No trial results
$ASMB (Hep B+D) 8/25 announces 94% reduction in Hep at 350 mil dose. Announces
$175 mil offer at
$19.60 with Gilead separate
$45 mil at
$19.60. Never went red. New 52 highs Fri @
$30.20
$QNRX (Netherton -extremely rare) No trial news. Announces PP on 10/10 in
$7's. Stock runs to
$41. Now
$16's. Up more than 100%
$QURE (Huntingtons - extremely rare) on 9/24 announces some trial progression for AMT-130. Stock runs
$13's to
$50 . Immed announce
$200 mil offering. Upsized to
$350 mil. Stock hits new 52's last wk
$64.
$IMRX (Pancreatic cancer) On 9/25 announces world's best survival rate at 6 mos of 94%. Further announcing survival rate of 86% at 9 mos vs. only FDA approved 42% in the market. Announces
$175 mil offering with PP from Sanofi
$25 mil. Identical to ASMB. Offering & placement @
$9.23 (no discount). Stock now
$5.58